CN116585234A - 一种蚊虫叮咬皮肤舒缓贴及其制备方法及使用方法 - Google Patents
一种蚊虫叮咬皮肤舒缓贴及其制备方法及使用方法 Download PDFInfo
- Publication number
- CN116585234A CN116585234A CN202310592389.2A CN202310592389A CN116585234A CN 116585234 A CN116585234 A CN 116585234A CN 202310592389 A CN202310592389 A CN 202310592389A CN 116585234 A CN116585234 A CN 116585234A
- Authority
- CN
- China
- Prior art keywords
- liquid
- parts
- mosquito
- soothing
- patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 70
- 206010003399 Arthropod bite Diseases 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 140
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 69
- 238000010521 absorption reaction Methods 0.000 claims abstract description 68
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000004744 fabric Substances 0.000 claims abstract description 26
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 16
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims abstract description 16
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 16
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 16
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 14
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 14
- 240000006891 Artemisia vulgaris Species 0.000 claims abstract description 14
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000001035 drying Methods 0.000 claims abstract description 14
- 229940041616 menthol Drugs 0.000 claims abstract description 14
- 238000002955 isolation Methods 0.000 claims abstract description 12
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims abstract description 11
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000008213 purified water Substances 0.000 claims abstract description 9
- 239000011505 plaster Substances 0.000 claims abstract description 5
- 239000012528 membrane Substances 0.000 claims description 65
- 239000002121 nanofiber Substances 0.000 claims description 65
- 239000000077 insect repellent Substances 0.000 claims description 50
- 239000000843 powder Substances 0.000 claims description 48
- 239000000853 adhesive Substances 0.000 claims description 39
- 230000001070 adhesive effect Effects 0.000 claims description 39
- 230000000844 anti-bacterial effect Effects 0.000 claims description 36
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 28
- 230000002745 absorbent Effects 0.000 claims description 23
- 239000002250 absorbent Substances 0.000 claims description 23
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 22
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 21
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 21
- 229910052901 montmorillonite Inorganic materials 0.000 claims description 21
- 239000000661 sodium alginate Substances 0.000 claims description 21
- 235000010413 sodium alginate Nutrition 0.000 claims description 21
- 229940005550 sodium alginate Drugs 0.000 claims description 21
- 239000002131 composite material Substances 0.000 claims description 18
- 239000003292 glue Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 17
- 239000002985 plastic film Substances 0.000 claims description 17
- 229920006255 plastic film Polymers 0.000 claims description 17
- 239000008367 deionised water Substances 0.000 claims description 14
- 229910021641 deionized water Inorganic materials 0.000 claims description 14
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 13
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 13
- 238000009987 spinning Methods 0.000 claims description 12
- 108010022355 Fibroins Proteins 0.000 claims description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 11
- 229960003638 dopamine Drugs 0.000 claims description 11
- 229940113115 polyethylene glycol 200 Drugs 0.000 claims description 11
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 10
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 10
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- 239000001263 FEMA 3042 Substances 0.000 claims description 9
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 229920002258 tannic acid Polymers 0.000 claims description 9
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 9
- 229940033123 tannic acid Drugs 0.000 claims description 9
- 235000015523 tannic acid Nutrition 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 244000178870 Lavandula angustifolia Species 0.000 claims description 6
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 6
- 238000010041 electrostatic spinning Methods 0.000 claims description 6
- 239000001102 lavandula vera Substances 0.000 claims description 6
- 235000018219 lavender Nutrition 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 6
- 229960004063 propylene glycol Drugs 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000002390 adhesive tape Substances 0.000 claims description 5
- 230000001680 brushing effect Effects 0.000 claims description 5
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 2
- 244000166675 Cymbopogon nardus Species 0.000 claims description 2
- 235000018791 Cymbopogon nardus Nutrition 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 2
- 240000000785 Tagetes erecta Species 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 abstract description 27
- 230000007803 itching Effects 0.000 abstract description 23
- 230000003020 moisturizing effect Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 description 44
- 239000010410 layer Substances 0.000 description 31
- 241000255925 Diptera Species 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 13
- 230000001139 anti-pruritic effect Effects 0.000 description 10
- 239000003908 antipruritic agent Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- -1 meanwhile Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920000867 polyelectrolyte Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000011229 interlayer Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 229920001046 Nanocellulose Polymers 0.000 description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000005213 imbibition Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000001846 repelling effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000002522 swelling effect Effects 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- YAXKTBLXMTYWDQ-UHFFFAOYSA-N 1,2,3-butanetriol Chemical compound CC(O)C(O)CO YAXKTBLXMTYWDQ-UHFFFAOYSA-N 0.000 description 1
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241001106462 Ulmus Species 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940083267 amaranthus caudatus seed extract Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000001522 artemisia absinthium l. herb extract Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940059958 centella asiatica extract Drugs 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical group C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910052604 silicate mineral Inorganic materials 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940119569 wormwood extract Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8129—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Medicinal Preparation (AREA)
Abstract
本申请涉及外用护肤产品领域,具体公开了一种蚊虫叮咬皮肤舒缓贴及其制备方法及使用方法。蚊虫叮咬皮肤舒缓贴包括舒缓贴和舒缓液,所述舒缓贴依次包括胶布层、粘贴在胶布层中央的吸液垫和粘附在胶布层上的隔离层;所述舒缓液包括以下重量份的组分:90‑98份纯化水、0.003‑0.02份次氯酸、0.01‑1份薄荷醇、0.03‑1份透明质酸钠、0.5‑5份艾草提取物、0.01‑1份聚乙二醇‑400、1‑2份丙二醇。本申请的蚊虫叮咬皮肤舒缓贴其具有止痒消肿速度快,不易干燥或挥发,作用时间持续长久,保湿时间长,不易被抹除的优点。
Description
技术领域
本申请涉及外用护肤产品技术领域,更具体地说,它涉及一种蚊虫叮咬皮肤舒缓贴及其制备方法及使用方法。
背景技术
夏季蚊虫肆虐,人体容易被蚊虫叮咬而引起皮肤局部瘙痒、红肿,甚至引起皮炎,而婴幼儿与儿童的皮肤表现会更加明显。并且,蚊虫叮咬之后,来自蚊虫的唾液、毒液和分泌物中含有多种抗原成分,进入人体皮肤后,会与人体内的抗体产生免疫反应,引起体内释放组胺,引起过敏,处理不当还会造成经久不褪的疤痕及色素沉淀,非常影响患者的日常工作和生活。
目前,市场上蚊虫叮咬止痒类产品琳琅满目,现有的用于蚊虫叮咬止痒舒缓的药物多为西药,如皮炎平、艾洛松等,这种凝胶类药物涂抹后,极易被衣物蹭掉而影响效果,而用于蚊虫叮咬的止痒涂抹液,如花露水、风油精等,疗效维持时间短,含有大量的乙醇等刺激性成分,容易刺激皮肤,且含有防腐剂等,对人体也具有一定的潜在风险,传统带有药物的贴覆型药物,药物易附着在纱布上,有效期短,会较快干燥并分解。
针对上述中的相关技术,发明人发现目前的蚊虫叮咬舒缓产品涂抹后,外部干扰多,易被抹除,且疗效保持时间有待提升。
发明内容
为了使蚊虫叮咬舒缓产品具有不易被抹除,延长其使用效果,本申请提供一种蚊虫叮咬皮肤舒缓贴及其制备方法及使用方法。
第一方面,本申请提供一种蚊虫叮咬皮肤舒缓贴,采用如下的技术方案:
一种蚊虫叮咬皮肤舒缓贴,包括舒缓贴和舒缓液,所述舒缓贴依次包括胶布层、粘贴在胶布层中央的吸液垫和粘附在胶布层上的隔离层;
所述舒缓液包括以下重量份的组分:90-98份纯化水、0.003-0.02份次氯酸、0.01-1份薄荷醇、0.03-1份透明质酸钠、0.5-5份艾草提取物、0.01-1份聚乙二醇-400、1-2份丙二醇。
通过采用上述技术方案,隔离层能将吸液垫保护在内,使吸液垫在储存时不易被污染,将隔离层去除后,将舒缓液滴加在吸液垫上,将吸液垫与蚊虫叮咬处接触,胶布层能将舒缓贴黏附在肌肤上,而且胶布层能保护吸液垫不易被抹除,延长了舒缓液的药效时间;舒缓液中含有次氯酸、艾草提取物等,因次氯酸不带电荷且分子量相对较低,因此比其他杀菌剂或抑菌剂更能穿透细胞壁,从而与微生物细胞的关键成分有机物发生氧化反应的速度更快,所以其消毒作用更加高效,能在较短时间内消灭细菌,达到止痒效果;艾草提取物可以止痒、消肿,而且具有香味,能达到驱除蚊虫的效果,当产品贴在蚊虫叮咬处以后,不仅能快速止痒,延长止痒效果,还能防止蚊虫叮咬;其中透明质酸钠、聚乙二醇-400和丙二醇作为保湿剂使用,能阻止吸液垫上吸附的舒缓液水分挥发,使吸液垫持续湿润状态,不易干燥,从而使疗效延长;薄荷醇呈现薄荷香气和清凉的肤感,能收缩微血管、舒缓发痒和发炎,具有抗敏、淡化疤痕、去皱嫩肤的功效。
可选的,所述透明质酸钠、聚乙二醇-400和丙二醇的质量比为1:0.5-1:1-1.5。
通过采用上述技术方案,使透明质酸钠、聚乙二醇-400和丙二醇三者的配比更加精准,由此获得保湿性强的舒缓液,能在吸液垫上保持更长时间的湿润效果,不易干燥,延长止痒、消肿效果。
可选的,所述吸液垫:将胶原蛋白肽、海藻酸钠、聚乙烯醇、聚氧化乙烯、无水硫酸钠和去离子水混合,静置脱泡,制成纺丝液,经静电纺丝,制成纳米纤维膜;
将所述纳米纤维膜在50-55℃的温水中水洗20-24h,经预冻后真空冷冻干燥,制成多孔纳米纤维膜,经裁剪,制成吸液垫。
通过采用上述技术方案,使用胶原蛋白肽、聚乙烯醇和海藻酸钠作为纳米纤维膜的原料,海藻酸钠中的-COO-与胶原蛋白中-NH3+之间产生氢键结合,增加了纺丝溶液的稳定性,且海藻酸钠与水分子接触时,会产生溶胀,增加纺丝液的浓度,提高纺丝液的表面张力,使纳米纤维的均匀性提升;藻酸钠吸水后是一个轻度交联的网络结构,由于海藻酸钠的亲水性基团-COOH与水分子形成氢键作用,使得空间网络结构扩展,网络内外产生渗透压差,使得海藻酸钠的吸水能力增强,带液率更高,使吸液垫能留存更多的舒缓液,同时,水分子会被困在海藻酸钠的网状结构中,能使纳米纤维素膜锁住更多的水分子,水分流失更慢,具有长效保水能力,不易干燥;以无水硫酸钠作为致孔剂,在纳米纤维中占据一定的空间,经水洗后去除,成孔剂能在纤维素膜上形成蜂窝状的孔隙结构,且孔径分布较均匀,孔隙结构饱满,孔隙率高,有利于舒缓液的吸附,也有利于纳米纤维膜与水分子之间氢键的形成,从而使含有较多孔隙的纳米纤维膜的吸水倍数和保湿倍数得到改善,吸液垫能吸附更多的舒缓液,且保湿时间长,能延长舒缓液的作用时间;而且聚乙烯醇是一种轻度交联的具有三维网状结构的高分子聚电解质,其大分子链上具有大量的亲水基团,依靠其内部的三维空间网络的作用,吸收大量的自由水储存在其中,使得网络空间扩展开来,发生溶胀,同样海藻酸钠也具有溶胀作用,吸收舒缓液后产生体积膨胀,使吸液垫的体积增大,能给叮咬处一定的压力作用,使吸液垫与皮肤接触面积增大,接触紧密,从而具有更好的消肿、止痒效果。
可选的,所述吸液垫所用原料重量份如下:15-18份胶原蛋白肽、0.5-0.8份海藻酸钠、2.3-2.5份聚乙烯醇、聚氧化乙烯3-4份、25-28份无水硫酸钠、去离子水78-85份。
通过采用上述技术方案,以上重量的各原料能制成具有多孔结构、吸附力强、带液率高、保湿能力好的吸液垫,防止舒缓液挥发失效。
可选的,所述多孔纳米纤维膜裁剪前,经过以下处理:
将聚乙二醇200溶解,制成浓度为4-5wt%的溶液,加入驱蚊抗菌粉末和蒙脱石,搅拌均匀后静置1-1.5h,制成处理液,聚乙二醇200、驱蚊抗菌粉末和蒙脱石的质量比为1:0.08-0.12:0.1-0.2;
将所述多孔纳米纤维膜浸泡在处理液中20-24h,取出后将多孔纳米纤维膜在0.01-0.03MPa下压制3-5h,然后在温度为37-40℃、湿度为0-5%的环境下干燥。
通过采用上述技术方案,聚乙二醇-200具有亲水性,其分子链上的羟基能与多孔纳米纤维膜上的羟基相互作用形成氢键,能大大提升纳米纤维膜的吸水能力和保水能力,并保持叮咬处稳定湿润的环境,能有效避免创面愈合过程中皮肤干燥引起银屑病或过敏性皮炎,具有黏附效果的聚乙二醇200还能改善驱蚊抗菌粉末、蒙脱石与多孔纳米纤维膜之间的结合稳定性,多孔结构的纳米纤维膜能持续释放驱蚊抗菌粉末,接触肌肤时,释放的驱蚊抗菌粉末能杀死细菌,释放驱蚊气味,蒙脱石是2:1结构的天然成长硅酸盐矿物,在水中易吸水膨胀,层间距增大,可吸附大量层间水和吸附水,能增强纳米纤维膜的吸水、保水性,而且蒙脱石与聚乙烯醇具有较好的亲和作用,蒙脱石能均匀分散在纳米纤维膜中,从而形成具有多孔、固水、缓释等功能的多孔纳米纤维膜;蒙脱石颗粒充分分散在纳米纤维膜网络间隙内,纤维水势高的一端溶胀,蒙脱石颗粒发生断桥,水分运移依靠纳米纤维膜吸脱附作用,多孔纳米纤维膜水势低的一端脱水,蒙脱石颗粒桥接形成传水通道,由此实现了由分子传水和层间传水能垒不一致导致的沿纤维纵向水势梯度变化而形成的水分运移的过程机制;采用先加压后干燥法,不仅利于多孔纳米纤维膜中的水分蒸发,加快多孔纳米纤维膜的干燥过程,而且保证多孔纳米纤维膜的整体干燥速率相对一致,在整个干燥过程中,多孔纳米纤维膜表面不会出现由局部应力引起的褶皱或收缩,此外持续的纵向加压使更多的舒缓液的液滴进入多孔纳米纤维膜的网络结构中并均匀分散。
可选的,所述胶布层包括塑料膜和粘结凝胶,粘结凝胶与吸液垫相互接触;
所述粘结凝胶的制法如下:将质量比为1:0.8-1的浓度为2-2.5wt%的丝素蛋白水溶液和浓度为10-12wt%的单宁酸溶液混合,静置0.5-1h,去除上清液,制得复合凝胶;
将氯化铁、柠檬酸与去离子水混合,加入多巴胺和驱蚊抗菌粉末,制成涂刷液,调节pH至8-12,涂刷在所述复合凝胶上,室温静置10-20min。
通过采用上述技术方案,单宁酸和丝素蛋白通过氢键作用结合,形成具有黏附作用且生物相容性较好的复合凝胶,丝素蛋白和单宁酸合成的复合凝胶具有无规则卷曲结构,柔性较好,丝素蛋白的分子链之间很容易发生缠绕,而当出现拉应力时,能改善复合凝胶的内聚力,改善复合凝胶的粘性;当肌肤收紧产生拉应力时,丝素蛋白卷曲结构提供了充分的柔性,当粘结凝胶受到拉伸时,丝素蛋白分子链能快速重排并与相邻的单宁酸分子形成可逆相互作用,达到优异的拉伸性能,不会使得粘结凝胶因拉力较大断裂、或与肌肤脱离;然后在复合凝胶上涂覆含有多巴胺、驱蚊抗菌粉末、柠檬酸等物质的混合液,多巴胺上具有大量的邻苯二酚活性基团,在弱碱性的环境下,邻苯二酚基团会发生氧化自聚合、席夫碱、迈克尔加成反应等,三价铁离子的加入使得邻苯二酚与Fe3+发生络合反应,从而在其之间形成配位键,实现了复合凝胶的粘性改善,使得粘结层与塑料膜和吸液垫粘结牢固,而且在粘结凝胶中添加驱蚊抗菌粉末,使粘结凝胶具有驱蚊效果,粘结凝胶与肌肤接触的范围比吸液垫大,而且粘结凝胶位于吸液垫的一周,能对与吸液垫接触的肌肤一周进行抗菌保护。
可选的,所述涂刷液中各组分的重量份如下:6.5-7重量份氯化铁、7.8-8重量份柠檬酸、2-3重量份去离子水、0.5-1重量份多巴胺和0.5-2重量份驱蚊抗菌粉末。
通过采用上述技术方案,以上各组分制成的涂刷液,能改善复合凝胶的粘性,增大复合凝胶的抗菌能力。
可选的,所述驱蚊抗菌粉末选自薄荷粉、万寿菊粉、薰衣草粉、香茅粉、迷迭香粉中的至少一种。
通过采用上述技术方案,薄荷粉中含有八种儿茶萘酚酸,是有效的抗炎剂,而且其散发的香味能驱除蚊虫,万寿菊、薰衣草、香茅和迷迭香均能起到杀菌、止痒和驱蚊的效果。
第二方面,本申请提供一种蚊虫叮咬皮肤舒缓贴的制备方法,采用如下的技术方案:
一种蚊虫叮咬皮肤舒缓贴的制备方法,包括以下步骤:
舒缓贴的制备:在塑料膜上涂覆粘结凝胶,制成胶布层,将吸液垫粘附在塑料膜中央,在塑料膜上粘附离型纸,将吸液垫覆盖在离型纸下,制成舒缓贴;
舒缓液的制备:将次氯酸、薄荷醇、艾草提取物加入到纯化水中,搅拌均匀后加入透明质酸钠、聚乙二醇-400和丙二醇,混匀,灌装,制成舒缓液;
将舒缓贴和舒缓液配套包装,制成蚊虫叮咬皮肤舒缓贴。
通过采用上述技术方案,将吸液垫与粘结凝胶接触,离型纸作为隔离层,将吸液垫覆盖在离型纸和塑料膜之间,能对吸液垫进行隔离,防止储存时吸液垫被污染;然后将舒缓液的各组分混合,灌注后制得舒缓液,将舒缓液和舒缓贴配套包装,配合使用,舒缓贴吸附舒缓液后,贴覆在肌肤上,受干扰因素少、不易被抹除。
第二方面,本申请提供一种蚊虫叮咬皮肤舒缓贴的使用方法,通过采用上述技术方案,
一种蚊虫叮咬皮肤舒缓贴的使用方法,包括以下步骤:
将隔离层去除,将舒缓液滴在吸液垫上,然后将胶布层带有吸液垫的一侧贴覆在被叮咬处,按压吸液垫四周的胶布层。
通过采用上述技术方案,使用方法简单,吸液垫被胶布层保护在内,不易被外界因素干扰,而且不易挥发,与肌肤接触时间长,止痒消肿效果好,疗效时间长。
综上所述,本申请具有以下有益效果:
1、由于本申请使用含有艾草提取物、薄荷醇、透明质酸钠、聚乙二醇-400等组分的舒缓液,而且还配合有与舒缓液共同使用的舒缓贴,舒缓液滴加在舒缓贴上的吸液垫上,舒缓贴能保护吸液垫不被外界因素干扰,不易被抹除,保持吸液垫润湿,延长疗效,且舒缓液具有止痒、消肿、杀菌、驱蚊的效果,其中还具有保湿成分,能降低舒缓液的挥发,防止其在较短时间内干燥而失去止痒消肿效果。
2、本申请中优选采用胶原蛋白肽、海藻酸钠和聚乙烯醇、无水硫酸钠制备纺丝液,然后经水洗后真空冷冻干燥,制成具有多孔结构的纳米纤维膜,作为致孔剂温度无水硫酸钠增大了纳米纤维膜的孔隙率,增加的其吸水性,而且海藻酸钠和聚乙烯醇具有溶胀作用,不仅吸水能力和保水性能强,而且吸水后体积膨胀,能增大吸液垫对肌肤叮咬处的压力,使胶布层变紧,能提供更大、更稳定的压力,获得更好的接触效果。
3、本申请中优选采用丝素蛋白和单宁酸作为原料,二者发生氢键作用,制成具有黏附力的复合凝胶,然后采用多巴胺与三价铁离子发生络合反应,形成配位键,改善粘结凝胶的粘附力,提高胶布层的粘结稳定性,防止水分沿胶布层和肌肤之间的孔隙进入,提高防水性,而且粘结凝胶中含有驱蚊抗菌粉末,使粘结凝胶具有驱蚊和抗菌效果。
具体实施方式
吸液垫的制备例1-9
制备例1:(1)将18g胶原蛋白肽、0.8g海藻酸钠、2.5g聚乙烯醇、4g聚氧化乙烯、28g无水硫酸钠和85g去离子水混合,静置脱泡,制成纺丝液,经静电纺丝,制成纳米纤维膜;静电纺丝参数为:电压为22KV,电流为16MA,接收距离为20cm,纺丝溶液推进速度为60μm/min,滚筒转速为100r/min;
(2)将所述纳米纤维膜在50℃的温水中水洗24h,经-10℃预冻2h后,在-35℃下真空冷冻干燥3h,制成多孔纳米纤维膜;
(3)将聚乙二醇200用去离子水溶解,制成浓度为5wt%的溶液,加入驱蚊抗菌粉末和蒙脱石,搅拌均匀后静置1.5h,制成处理液,聚乙二醇200、驱蚊抗菌粉末和蒙脱石的质量比为1:0.12:0.2,驱蚊抗菌粉末为薰衣草粉,驱蚊抗菌粉末和蒙脱石的粒径为1250目,薰衣草粉由薰衣草经晾晒后粉碎,与其质量0.1倍的硬脂酸钙混合制成;
将步骤(2)制成的多孔纳米纤维膜浸泡在处理液中24h,取出后将多孔纳米纤维膜置于两个可透气的多孔聚四氟乙烯平板之间,施加0.03MPa下压制3h,然后在温度为37℃、湿度为0%的环境下干燥3h;
(4)将步骤(3)所得多孔纳米纤维膜经裁剪,制成吸液垫。
制备例2:将15g胶原蛋白肽、0.5g海藻酸钠、2.3g聚乙烯醇、3g聚氧化乙烯、25g无水硫酸钠和78g去离子水混合,静置脱泡,制成纺丝液,经静电纺丝,制成纳米纤维膜;静电纺丝参数为:电压为22KV,电流为16MA,接收距离为20cm,纺丝溶液推进速度为60μm/min,滚筒转速为100r/min;
将所述纳米纤维膜在55℃的温水中水洗20h,经-10℃预冻2h后,在-35℃下真空冷冻干燥3h,制成多孔纳米纤维膜;
(3)将聚乙二醇200用去离子水溶解,制成浓度为4wt%的溶液,加入驱蚊抗菌粉末和蒙脱石,搅拌均匀后静置1h,制成处理液,聚乙二醇200、驱蚊抗菌粉末和蒙脱石的质量比为1:0.08:0.1,驱蚊抗菌粉末为薄荷粉,驱蚊抗菌粉末和蒙脱石的粒径为1250目,薄荷粉由薄荷叶经晾晒后粉碎,与其质量0.1倍的硬脂酸钙混合制成;
将步骤(2)制成的多孔纳米纤维膜浸泡在处理液中20h,取出后将多孔纳米纤维膜置于两个可透气的多孔聚四氟乙烯平板之间,施加0.01MPa下压制5h,然后在温度为40℃、湿度为5%的环境下干燥2h;
(4)将步骤(3)所得多孔纳米纤维膜经裁剪,制成吸液垫。
制备例3:与制备例1的区别在于,步骤(1)中未添加无水硫酸钠。
制备例4:与制备例1的区别在于,步骤(1)中未添加海藻酸钠。
制备例5:与制备例1的区别在于,步骤(1)中未添加聚乙烯醇。
制备例6:与制备例1的区别在于,未进行步骤(3)。
制备例7:与制备例1的区别在于,步骤(3)中未添加驱蚊抗菌粉末。
制备例8:与制备例1的区别在于,步骤(3)中未添加蒙脱石。
制备例9:与制备例1的区别在于,步骤(3)中将多孔纳米纤维膜浸泡处理液后,不施加压力,在37℃下干燥。
粘结凝胶的制备例10-14
制备例10:(1)将质量比为1:1的浓度为2.5wt%的丝素蛋白水溶液和浓度为12wt%的单宁酸溶液混合,静置1h,去除上清液,制得复合凝胶;
(2)将7g氯化铁和8g柠檬酸与3g去离子水混合,加入1g多巴胺和2g驱蚊抗菌粉末,调节pH至12,涂刷在所述复合凝胶上,室温静置20min。
制备例11:(1)将质量比为1:0.8的浓度为2wt%的丝素蛋白水溶液和浓度为10wt%的单宁酸溶液混合,静置0.5h,去除上清液,制得复合凝胶;
(2)将6.5g氯化铁和7.8g柠檬酸与2g去离子水混合,加入0.5g多巴胺和0.5g驱蚊抗菌粉末,调节pH至8,涂刷在所述复合凝胶上,室温静置10min。
制备例12:与制备例10的区别在于,步骤(2)中未添加氯化铁和柠檬酸。
制备例13:与制备例10的区别在于,未添加驱蚊抗菌粉末
制备例14:与制备例10的区别在于,未进行步骤(2)。
实施例
实施例1:一种蚊虫叮咬皮肤舒缓贴,包括舒缓贴和舒缓液,舒缓贴依次包括胶布层、吸液垫和隔离层,吸液垫粘附在胶布层上,隔离层粘附在胶布层上,且将吸液垫覆盖在隔离层和胶布层之间;隔离层为离型纸,胶布层包括PVC塑料膜和粘结凝胶,粘结凝胶由制备例10制成,粘结凝胶与吸液垫相互接触,吸液垫由制备例1制成,舒缓液包括以下重量的原料:98kg纯化水、0.02kg次氯酸、1kg薄荷醇、1kg透明质酸钠、5kg艾草提取物、1kg聚乙二醇400和1.5kg丙二醇,艾草提取物的制备方法为:将艾草粉碎,加入重量体积比为10:1的水,超声15min,过滤,去除滤液,滤渣中加入重量体积比为25:1的70%的乙醇,过滤,滤渣用同样的方法再提取一次,合并两次的滤液,浓缩、干燥、粉碎制成。
上述蚊虫叮咬皮肤舒缓贴的制备方法,包括以下步骤:
S1、舒缓贴的制备:在PVC塑料膜上涂覆粘结凝胶,制成胶布层,将吸液垫粘附在塑料膜中央,在塑料膜上粘附离型纸,将吸液垫覆盖在离型纸下,制成舒缓贴,粘结凝胶在PVC塑料膜上的涂覆量为20g/m2;
S2、舒缓液的制备:将次氯酸、薄荷醇、艾草提取物加入到纯化水中,搅拌均匀后加入透明质酸钠、聚乙二醇-400和丙二醇,混匀,灌装,制成舒缓液;
S3、将舒缓贴和舒缓液配套包装,制成蚊虫叮咬皮肤舒缓贴。
实施例2;一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,胶布层包括TPU塑料膜和粘结凝胶,粘结凝胶由制备例11制成,粘结凝胶与吸液垫相互接触,吸液垫由制备例2制成,舒缓液的原料重量如下:94kg纯化水、0.01kg次氯酸、0.5kg薄荷醇、1kg透明质酸钠、3kg艾草提取物、0.5kg聚乙二醇400和1kg丙二醇。
实施例3:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,舒缓液包括以下重量的原料:90kg纯化水、0.003kg次氯酸、0.01kg薄荷醇、0.03kg透明质酸钠、0.5kg艾草提取物、0.01kg聚乙二醇400和2kg丙二醇。
实施例4:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,吸液垫由制备例3制成。
实施例5:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,吸液垫由制备例4制成。
实施例6:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,吸液垫由制备例5制成。
实施例7:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,吸液垫由制备例6制成。
实施例8:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,吸液垫由制备例7制成。
实施例9:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,吸液垫由制备例8制成。
实施例10:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,吸液垫由制备例9制成。
实施例11:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,粘结凝胶由制备例12制成。
实施例12:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,粘结凝胶由制备例13制成。
实施例13:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,粘结凝胶由制备例14制成。
实施例14:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,粘结凝胶选自市售纯天然马来胶,将医用纯天然马来胶热熔后,涂覆在塑料膜上,制成胶布层。
对比例
对比例1:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,未添加艾草提取物。
对比例2:一种蚊虫叮咬皮肤舒缓贴,与实施例1的区别在于,未添加薄荷醇。
对比例3:一种蚊虫叮咬舒缓液,包括以下重量份的组分:植物提取物包括樟脑1份、薄荷醇0.6份、尾穗苋籽提取物0.4份、春榆根提取物0.02份、无花果提取物0.05份、积雪草提取物0.01份;皮肤调理剂包括0.03份普鲁兰多糖、0.05份乙基己基甘油、0.1份柠檬酸钠、0.05份柠檬酸、0.25份甘油、0.01份氢化卵磷脂、0.001份神经酰胺-3;二醇类化合物包括10份甲基丙三醇、0.25份丁二醇、0.2份1,2-己二醇,稳定剂为0.03份乙二胺四乙酸二钠,乳化剂为0.05份C12-14链烷醇聚醚-12,增溶剂为0.01份氢化蓖麻油、溶剂包括46.98份水和40份乙醇。制备方法:取相应量乳化剂、增溶剂和二元醇类化合物加入相应量的溶剂中,加热至75℃搅拌溶解,降温至40℃,加入相应量的皮肤调理剂、植物提取物和稳定剂,混合均匀,过滤,即得。
性能检测试验
一、按照实施例和对比例中方法制备舒缓贴和舒缓液,按照以下方法进行性能检测,将检测结果记录于表1中。
1、止痒消肿效果:首先按照GB/T 13917.9-2009中攻击力试验的方法筛选合格的测试人员和试虫,攻击力合格的测试人员被蚊虫叮咬后有瘙痒感、皮肤起包并且发红才可进行止痒测试。测试人员180人(年龄20-45岁),将测试人员分为18组,每组10人,分别是实施例1-14组、对比例1-3组、空白对照组。测试人员手背露出4cm*4cm面积的测试区域,其余部位严密遮蔽,测试人员将手放入蚊笼至蚊虫前来叮咬后10s快速取出,将制成的制成温度蚊虫叮咬皮肤舒缓贴上隔离层去除,将舒缓液滴2-3滴在吸液垫上,将粘结凝胶贴敷在蚊虫叮咬处,对比例3中涂抹舒缓液0.04mL,并计时,记录皮肤瘙痒过程的时间(止痒时间)t1和包块消失的时间(消包时间)t2。
2、蚊虫趋避率:在志愿者的双手背上贴上舒缓贴,对比例3中舒缓液涂覆在手背上,涂覆面积为4cm×4cm,将志愿者的手臂其余部分严密遮蔽,伸入密闭的容器中,向容器中放入20只白纹伊蚊,记录30min内停留在测试部位的蚊虫数目,计算趋避率,每个实施例或对比例的志愿者为10名,取检测平均值。
3、吸水性:将吸液垫裁剪成2.5cm×2.5cm的样品,在37℃的温度下在舒缓液中浸泡,在1h时取出,用滤纸吸取表面舒缓液,并称重M1,浸泡前吸液垫重量为M0,按照下式计算吸水率:S=(M1-M0)/M0×100%,每个实施例测试三个样品,计算平均值。
4、保水性:将吸液垫裁剪成2.5cm×2.5cm的样品,在37℃的恒温下,在舒缓液中浸泡,在浸泡前记录样品的重量为M0,当吸水率达到平衡时,记录其质量为M1,在1h时从舒缓液中取出样品,滤纸吸取表面舒缓液,并记录其质量M2,保水率按照下式计算:G=(M1-M0)/(M2-M0)×100%,每个实施例测试三个样品,计算平均值。
表1蚊虫叮咬皮肤舒缓贴的效果检测
结合表1内检测数据,可以看出,实施例1和实施例2中分别使用制备例1和制备例2制成的吸液垫,且分别使用制备例10和制备例11制成温度粘结凝胶,表1内显示,实施例1和实施例2制备的舒缓贴黏附在被叮咬处以后,能在较短时间内止痒和消肿,而且吸液垫的吸水性和保水性好,不会在较短时间内失水干燥,另外还具有较好的防蚊效果。
实施例3中改变透明质酸钠、聚乙二醇400和丙二醇的质量比,制成的舒缓液的驱蚊效果不及实施例1,可见其驱蚊效果有所下降,说明使用适宜用量的透明质酸钠、聚乙二醇400和丙二醇,在吸液垫上能延长吸液垫的保湿时间,改善止痒、驱蚊持久性。
实施例4与实施例1相比,使用制备例3制成的吸液垫,制备例3中未添加无水硫酸钠,由表1内数据可见,实施例4制备的舒缓贴的止痒、消肿时间增加,驱蚊效果减弱,而且吸水率下降,说明未在纳米纤维膜上致孔,会导致吸液垫的吸液效果减弱,吸收舒缓液的量减少,驱蚊和止痒效果减弱。
实施例5中使用制备例4制成的吸液垫,制备例4中未添加海藻酸钠,与表1相比,实施例5制备的舒缓贴吸水率下降,保水性下降,止痒和消肿时间增加,驱蚊效果变化不大,说明海藻酸钠能改善吸液垫的保水性和吸水率,增加舒缓液的吸收量和保湿性,防止舒缓液较快干燥,影响其止痒和消包效果。
实施例6与实施例1的区别是,使用了制备例5制成的吸液垫,制备例5中未添加聚乙烯醇,实施例6与实施例5相似,制成的舒缓贴的保湿性和吸水性下降,止痒和消肿效果减弱。
实施例7-9中分别使用制备例6-8制成的吸液垫,制备例6与制备例1相比,未将多孔纳米纤维膜进行预处理,制备例7和制备例8中在预处理多孔纳米纤维膜时,分别未添加驱蚊抗菌粉末和蒙脱石,实施例7制备的舒缓贴吸水率和保水率下降,止痒和消肿时间增大,而且蚊虫趋避效果减弱,说明对多孔纳米纤维膜进行预处理,能改善舒缓贴的保水率和吸水率,能增加舒缓液在吸液垫内的留存时间,降低挥发量;实施例8中未添加驱蚊抗菌粉末,舒缓贴的吸水率和保水率与实施例1相近,但蚊虫趋避效果下降,而且消肿和止痒效果稍有增加;实施例9中未添加蒙脱石,其保水和吸水能力与实施例1差,但比实施例7强,说明蒙脱石的加入,改善了多孔纳米纤维膜的吸水和保湿能力,能降低舒缓液的挥发,改善止痒效果。
实施例10与实施例1相比,使用了制备例9制成的吸液垫,在预处理多孔纳米纤维膜时,未在多孔纳米纤维膜上施加压力,制成的舒缓贴的驱蚊效果减弱,止痒和消肿时间稍有增加,说明在多孔纳米纤维膜上施加压力,能在多孔纳米纤维膜上负载较多驱蚊抗菌粉末和蒙脱石。
实施例11与实施例1相比,使用制备例12制成的粘结凝胶,未添加氯化铁和柠檬酸,表1内显示,实施例11制备的舒缓贴中止痒和消肿效果,表1内显示,实施例11制备的舒缓贴的止痒效果和消肿效果有所下降,但下降并不明显。
实施例12中使用制备例13制成的粘结凝胶,未添加驱蚊抗菌粉末,与实施例1相比,实施例12制备的舒缓贴的蚊虫趋避效果减弱。
实施例13中使用制备例14制成的粘结凝胶,未在复合凝胶上涂覆含有氯化铁、柠檬酸和多巴胺的溶液,与实施例1相比,实施例13制备的舒缓贴的止痒时间增加,消肿效果减弱,但驱蚊效果和保湿、吸水能力变化不大。
实施例14中使用市售的医用胶,与实施例1相比,实施例14制备的舒缓贴的蚊虫趋避效果减弱,而且消肿和止痒时间延长。
对比例1中未添加艾草提取物,对比例2中未添加薄荷醇,与实施例1相比,对比例1和对比例2制备的舒缓贴的止痒、消肿效果明显减弱,驱蚊效果降低。
对比例3为现有技术制备的蚊虫叮咬舒缓液,其采用涂抹或喷雾的形式使用,极易挥发,止痒和消肿效果不及实施例1,而且驱蚊效果较差。
二、按照实施例1和实施例11-13中的方法制备舒缓贴,并以5cm×3cm的猪皮作为贴敷对象,将舒缓液滴2-3滴在舒缓贴上,贴敷在猪皮上,试验时,使用100N传感器,设置拉伸速率为10mm/min,每个实施例设置5个平行试样,通过计算最大载荷与黏附面积的比值得到黏附强度,将检测结果记录于表2中。
表2蚊虫叮咬皮肤舒缓贴的黏附强度
由表2内数据可以看出,实施例1中使用制备例10制成的粘结凝胶,舒缓贴的黏附强度高,而实施例11中使用制备例12制成的粘结凝胶,其黏附强度有所下降,实施例12中因粘结强度中未添加驱蚊抗菌粉末,制成的粘结凝胶的黏附强度变化不大,实施例13中未采用含有氯化铁、多巴胺等组分的溶液涂覆复合凝胶,制成的粘结凝胶的黏附强度比实施例1和实施例11更低。
本具体实施例仅仅是对本申请的解释,其并不是对本申请的限制,本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改,但只要在本申请的权利要求范围内都受到专利法的保护。
Claims (10)
1.一种蚊虫叮咬皮肤舒缓贴,其特征在于,包括舒缓贴和舒缓液,所述舒缓贴依次包括胶布层、粘贴在胶布层中央的吸液垫和粘附在胶布层上的隔离层;
所述舒缓液包括以下重量份的组分:90-98份纯化水、0.003-0.02份次氯酸、0.01-1份薄荷醇、0.03-1份透明质酸钠、0.5-5份艾草提取物、0.01-1份聚乙二醇-400、1-2份丙二醇。
2.根据权利要求1所述的蚊虫叮咬皮肤舒缓贴,其特征在于:所述透明质酸钠、聚乙二醇-400和丙二醇的质量比为1:0.5-1:1-1.5。
3.根据权利要求1所述的蚊虫叮咬皮肤舒缓贴,其特征在于,所述吸液垫:将胶原蛋白肽、海藻酸钠、聚乙烯醇、聚氧化乙烯、无水硫酸钠和去离子水混合,静置脱泡,制成纺丝液,经静电纺丝,制成纳米纤维膜;
将所述纳米纤维膜在50-55℃的温水中水洗20-24h,经预冻后真空冷冻干燥,制成多孔纳米纤维膜,经裁剪,制成吸液垫。
4.根据权利要求3所述的蚊虫叮咬皮肤舒缓贴,其特征在于,所述吸液垫所用原料重量份如下:15-18份胶原蛋白肽、0.5-0.8份海藻酸钠、2.3-2.5份聚乙烯醇、聚氧化乙烯3-4份、25-28份无水硫酸钠、去离子水78-85份。
5.根据权利要求3所述的蚊虫叮咬皮肤舒缓贴,其特征在于,所述多孔纳米纤维膜裁剪前,经过以下处理:
将聚乙二醇200溶解,制成浓度为4-5wt%的溶液,加入驱蚊抗菌粉末和蒙脱石,搅拌均匀后静置1-1.5h,制成处理液,聚乙二醇200、驱蚊抗菌粉末和蒙脱石的质量比为1:0.08-0.12:0.1-0.2;
将所述多孔纳米纤维膜浸泡在处理液中20-24h,取出后将多孔纳米纤维膜在0.01-0.03MPa下压制3-5h,然后在温度为37-40℃、湿度为0-5%的环境下干燥。
6.根据权利要求1所述的蚊虫叮咬皮肤舒缓贴,其特征在于,所述胶布层包括塑料膜和粘结凝胶,粘结凝胶与吸液垫相互接触;
所述粘结凝胶的制法如下:将质量比为1:0.8-1的浓度为2-2.5wt%的丝素蛋白水溶液和浓度为10-12wt%的单宁酸溶液混合,静置0.5-1h,去除上清液,制得复合凝胶;
将氯化铁、柠檬酸与去离子水混合,加入多巴胺和驱蚊抗菌粉末,制成涂刷液,调节pH至8-12,涂刷在所述复合凝胶上,室温静置10-20min。
7.根据权利要求6所述的蚊虫叮咬皮肤舒缓贴,其特征在于,所述涂刷液中各组分的重量份如下:6.5-7重量份氯化铁、7.8-8重量份柠檬酸、2-3重量份去离子水、0.5-1重量份多巴胺和0.5-2重量份驱蚊抗菌粉末。
8.根据权利要求5或6所述的蚊虫叮咬皮肤舒缓贴,其特征在于,所述驱蚊抗菌粉末选自薄荷粉、万寿菊粉、薰衣草粉、香茅粉、迷迭香粉中的至少一种。
9.权利要求1-8任一项所述的蚊虫叮咬皮肤舒缓贴的制备方法,其特征在于,包括以下步骤:
舒缓贴的制备:在塑料膜上涂覆粘结凝胶,制成胶布层,将吸液垫粘附在塑料膜中央,在塑料膜上粘附离型纸,将吸液垫覆盖在离型纸下,制成舒缓贴;
舒缓液的制备:将次氯酸、薄荷醇、艾草提取物加入到纯化水中,搅拌均匀后加入透明质酸钠、聚乙二醇-400和丙二醇,混匀,灌装,制成舒缓液;
将舒缓贴和舒缓液配套包装,制成蚊虫叮咬皮肤舒缓贴。
10.权利要求1-8任一项所述的蚊虫叮咬皮肤舒缓贴的使用方法,其特征在于,包括以下步骤:
将隔离层去除,将舒缓液滴在吸液垫上,然后将胶布层带有吸液垫的一侧贴覆在被叮咬处,按压吸液垫四周的胶布层。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310592389.2A CN116585234A (zh) | 2023-05-24 | 2023-05-24 | 一种蚊虫叮咬皮肤舒缓贴及其制备方法及使用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310592389.2A CN116585234A (zh) | 2023-05-24 | 2023-05-24 | 一种蚊虫叮咬皮肤舒缓贴及其制备方法及使用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116585234A true CN116585234A (zh) | 2023-08-15 |
Family
ID=87607771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310592389.2A Pending CN116585234A (zh) | 2023-05-24 | 2023-05-24 | 一种蚊虫叮咬皮肤舒缓贴及其制备方法及使用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116585234A (zh) |
-
2023
- 2023-05-24 CN CN202310592389.2A patent/CN116585234A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1084716B1 (de) | Wundauflage zur gesteuerten Abgabe von Wirkstoff an Wunden und Verfahren zu ihrer Herstellung | |
US20160256366A1 (en) | Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor | |
FI77783C (fi) | Foer medicinska aendamaol avsedd vaetskeimpregnerad saordyna. | |
CA1254509A (en) | Bacteria adsorbing composition | |
CN101657222B (zh) | 带有细菌吸附组合物和持水系统的伤口敷料 | |
US20160106657A9 (en) | Cosmetic Treatment with Nitric Oxide, Device for Performing Said Treatment and Manufacturing Method Therefor | |
EA010316B1 (ru) | Перевязочный материал на основе целлюлозы микробного происхождения, его применение и содержащий его набор | |
CA2386810A1 (en) | Electrospun skin masks and uses thereof | |
KR20090027838A (ko) | 수분 감응성 피브리드즈 조성물 및 그 제조방법 | |
CN110960456A (zh) | 一种舒敏保湿冻干面膜及其制备方法 | |
EP2532326B1 (de) | Wundauflage, enthalted vliesstoff und salbengrundlage, zur unterdrucktherapie | |
CN107296975A (zh) | 一种抗菌止血复合医用敷料及其制备方法 | |
Bülbül et al. | Traditional and advanced wound dressings: physical characterization and desirable properties for wound healing | |
CN109222534A (zh) | 一种枕套 | |
CN116585234A (zh) | 一种蚊虫叮咬皮肤舒缓贴及其制备方法及使用方法 | |
CN101147744A (zh) | 甲壳素水溶气雾剂和伤口贴敷块组合药物 | |
CN112023110B (zh) | 一类基于竹荪蛋提取物的活性抑菌敷料 | |
CN108703895A (zh) | 一种深层渗透的长效保湿凝胶及制备方法 | |
KR101712023B1 (ko) | 한지에 홍삼을 적층시킨 마스크팩 및 이의 제조방법 | |
KR102274598B1 (ko) | 수용성 고분자 및 비수용성 고분자가 복합된 나노섬유 마스크 시트 | |
KR102446859B1 (ko) | 마스크 시트의 제조방법 및 이로부터 제조된 마스크 시트 | |
CN104606709A (zh) | 含有壳聚糖混合液的敷料内层及其制备方法 | |
KR101709290B1 (ko) | 하이드로겔 조성물 및 그것으로 이루어진 하이드로겔층을 포함하는 하이드로겔 시트 제품 | |
CN115721674B (zh) | 一种创口护理用组合物及其应用 | |
KR102372137B1 (ko) | 보습용 크림 조성물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |